

EIP



JIPLP: Insufficiency finally upheld as ground for invalidity of antibody claim

The Journal of Intellectual Property Law and Practice has published an article by partner Darren Smyth about the judgement in Eli Lilly & Company v Janssen Alzheimer Immunotherapy.

Mr Justice Arnold determines that a patent directed towards antibodies to β -amyloid peptide, for the treatment of Alzheimer's disease, is invalid for insufficiency.

To read the JIPLP article in full, click [here](#).